2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School, discusses findings from the phase 3 TiNivo-2 trial (NCT04987203) investigating tivozanib (Fotivda) plus nivolumab (Opdivo) vs tivozanib monotherapy in patients with metastatic renal cell carcinoma (RCC) who had previously progressed on or after an immune checkpoint inhibitor (ICI).